C-6VCITelomir Pharmaceuticals
epigenetics, metabolism, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6VCI
C-6VCIC-6VCIepigenetics, metabolism, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Telomir Pharmaceuticals states that TELOMIR-1 is being developed to lengthen protective telomere caps in pursuit of age reversal, and that excess unregulated metal-induced enzymatic activity drives oxidation, inflammation, cancerous mutations, and diseases such as hemochromatosis. The company presents the view that selectively binding metals like iron, copper, and zinc can inhibit harmful enzyme activity, restore metal homeostasis, and interrupt underlying processes involved in cancer development and related disease.
SourceTelomir Pharmaceuticals presents aging and age-related disease as a consequence of telomere shortening during cell division, which degrades genetic material when DNA can no longer be copied accurately end-to-end. The company states that Telomir 1 modulates telomerase to repair and lengthen telomeres, restore high-fidelity DNA replication, and protect stem cells by sustaining telomere-driven self-renewal, with potential therapeutic relevance for age-related inflammatory conditions.
SourceTelomir Pharmaceutical presents Telomir 1 as a novel small molecule intended to regulate telomere length and genomic stability by selectively binding critical metals such as iron, copper, and zinc. The company states that while metal reactivity is necessary for healthy maturity, excessive and unregulated metal-induced enzymatic activity contributes to oxidation, inflammation, cancerous mutations, and diseases such as hemochromatosis, and it believes that limiting available metals to restore homeostasis may interrupt these disease-driving processes.
Source